Bigfoot Biomedical gets FDA clearance for ‘smart’ insulin pen caps
The startup received 510(k) clearance for its “smart” insulin pen cap, which pulls in data from users’ connected glucose monitor to help them calculate the right dose.
The startup received 510(k) clearance for its “smart” insulin pen cap, which pulls in data from users’ connected glucose monitor to help them calculate the right dose.
The company is rolling out Level2, a digital health program for patients with type 2 diabetes. It uses wearable devices and coaches to help users manage their health.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Navigate4Me relies on trained care navigators who act as a point person for a patient's healthcare needs by assisting in clinical or administrative tasks, following up on treatment plans and connecting people to social or community-based support like transportation or housing assistance.
Medtronic said the company will be rolled into its Diabetes Group to improve its diabetes management capabilities by adding Nutrino's comprehensive food database, food analysis system and nutrition-science expertise.
With the FDA approval of a new continuous glucose monitoring system with machine learning capabilities to predict highs and lows in blood-glucose levels, Medtronic makes a bigger play for type 2 diabetes patients.
Medtronic is giving diabetes patients on insulin injection therapy outside the U.S. the ability to view blood glucose data from their continuous glucose monitors on their smartphones.
A low-cost, connected continuous glucose monitor that can provide clinical decision support seems like it would be a nice addition to the toolset of Diabeter, a Danish operator of Diabetes clinics, which Medtronic acquired last year.
More big news for Dexcom. Its G5 continuous glucose monitor will soon be available for use in several European countries.
DexCom has partnered with Google's life sciences arm to build a next-gen continuous glucose monitor. The new devices, expected out in the next 2-3 years, will be much smaller and cheaper, the companies say.
Bigfoot Biomedical is building an artificial pancreas, combining continuous glucose monitor tech with an insulin pump - and raising some capital to do so.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.